Purpose of this Study
We are doing this study to find out if it is necessary to treat people with antibiotics after nasal surgery. We want to know if antibiotics are helpful or not during the healing process after surgery.
Who Can Participate?
Eligibility
Adults ages 18+ who are scheduled for nasal surgery.
For more information about who can join this study, please contact the study team at revital.benvenisti@duke.edu or 919-668-5328.
For more information about who can join this study, please contact the study team at revital.benvenisti@duke.edu or 919-668-5328.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
If you choose to join this study, you will get a random assignment (like a coin flip) to 1 of 2 treatment arms in this study:<ul>
<li>If you are in Arm 1, you will get an antibiotic (either cefazolin or clindamycin) through IV (injected into a vein) during your surgery and not take any antibiotics on your own after surgery</li>
<li>If you are in Arm 2, you will get an antibiotic (either cefazolin or clindamycin) through IV (injected into a vein)</li></ul>
About a week after surgery, you will have a follow-up visit to see how you are doing. About 2 weeks after surgery, we will call you to see how you are doing.
<li>If you are in Arm 1, you will get an antibiotic (either cefazolin or clindamycin) through IV (injected into a vein) during your surgery and not take any antibiotics on your own after surgery</li>
<li>If you are in Arm 2, you will get an antibiotic (either cefazolin or clindamycin) through IV (injected into a vein)</li></ul>
About a week after surgery, you will have a follow-up visit to see how you are doing. About 2 weeks after surgery, we will call you to see how you are doing.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
Antibiotic prophylaxis in Rhinoplasty: A Randomized Controlled Trial
Principal Investigator
Charles
Woodard
Protocol Number
PRO00107781
NCT ID
NCT04194216
Phase
N/A
Enrollment Status
Open to Enrollment